

## ***Obstetrics Grand Rounds: Cell-free DNA for Recessive Disorders***

### **References**

Bonnel AS, Bihouée T, Ribault M, Driessen M, Grèvent D, et al; MODUL-CF study group. First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study. *J Cyst Fibros*. 2025 May;24(3):457-465. doi: 10.1016/j.jcf.2025.03.009. Epub 2025 Mar 24. PMID: 40133101.

Committee Opinion No. 691: Carrier Screening for Genetic Conditions. *Obstet Gynecol*. 2017 Mar;129(3):e41-e55. doi: 10.1097/AOG.0000000000001952. PMID: 28225426.

Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, et al; ACMG Professional Practice and Guidelines Committee. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021 Oct;23(10):1793-1806. doi: 10.1038/s41436-021-01203-z. Epub 2021 Jul 20. Erratum in: *Genet Med*. 2021 Oct;23(10):2015. doi: 10.1038/s41436-021-01300-z. PMID: 34285390; PMCID: PMC8488021.

Metcalf A, Hoppe JE, Martiniano SL, Zaretsky MV, Zemanick ET, Sagel SD. In Utero CFTR Modulator Therapy in Fetuses With Cystic Fibrosis. *Neoreviews*. 2026 Mar 1;27(3):e157-e169. doi: 10.1542/neo.27-3-103. PMID: 41763571.

Woodward, Paula J. *Diagnostic Imaging. Obstetrics*. Third edition. Philadelphia, PA: Elsevier, 2016.